Measuring Antibody Binding in Cancer Treatment
Author Information
Author(s): J.G. Fjeld, H.B. Benestad, T. Stigbrand, K. Nustad
Primary Institution: The Norwegian Radium Hospital
Hypothesis
Is the low tumor uptake of labeled monoclonal antibodies due to impaired antibody avidity in vivo?
Conclusion
The study found that the in vivo antibody avidity is not significantly different from in vitro, suggesting that low tumor uptake is not due to impaired avidity.
Supporting Evidence
- The association constant measured in vivo was similar to that measured in vitro.
- Low tumor uptake is attributed to factors other than antibody avidity.
- Antibody uptake was systematically varied using different particle concentrations.
Takeaway
The researchers wanted to see if antibodies used in cancer treatment work as well in living mice as they do in test tubes. They found that the antibodies worked just as well in both cases.
Methodology
The study used an artificial tumor model with diffusion chambers filled with antigen-coated particles implanted in mice, measuring antibody uptake after injection.
Limitations
The study's findings may not fully represent all tumor types or conditions due to the artificial model used.
Participant Demographics
Randomly bred female NMRI/BOM mice, aged 8-12 weeks.
Want to read the original?
Access the complete publication on the publisher's website